Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E52.81 EPS (ttm)6.87 Insider Own1.40% Shs Outstand104.40M Perf Week-0.52%
Market Cap37.85B Forward P/E25.56 EPS next Y14.18 Insider Trans-0.63% Shs Float77.49M Perf Month-2.47%
Income797.40M PEG2.84 EPS next Q3.11 Inst Own70.80% Short Float3.45% Perf Quarter-1.57%
Sales4.73B P/S8.00 EPS this Y85.10% Inst Trans0.17% Short Ratio2.70 Perf Half Y-6.92%
Book/sh42.84 P/B8.46 EPS next Y21.63% ROA13.00% Target Price435.82 Perf Year-21.45%
Cash/sh13.49 P/C26.88 EPS next 5Y18.63% ROE20.00% 52W Range325.35 - 484.57 Perf YTD-1.23%
Dividend- P/FCF45.17 EPS past 5Y44.90% ROI16.00% 52W High-25.18% Beta1.45
Dividend %- Quick Ratio3.40 Sales past 5Y55.00% Gross Margin92.90% 52W Low11.44% ATR11.41
Employees4300 Current Ratio3.60 Sales Q/Q7.30% Oper. Margin25.60% RSI (14)42.62 Volatility2.23% 2.89%
OptionableYes Debt/Eq0.09 EPS Q/Q25.30% Profit Margin16.90% Rel Volume0.79 Prev Close363.41
ShortableYes LT Debt/Eq0.09 EarningsFeb 03 BMO Payout0.00% Avg Volume991.16K Price362.56
Recom2.30 SMA20-2.18% SMA50-5.26% SMA200-6.41% Volume781,420 Change-0.23%
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $700 → $525
Jan-20-17 08:19AM  Regeneron Pharmaceuticals Could Be Ready to Rebound
06:29AM  Here are the stock markets biggest winners and losers during Obamas presidency at MarketWatch
Jan-19-17 12:55PM  These Insiders Are Still Finding Some Good Value in the Stock Market
11:11AM  A Green Light on Bayer
Jan-18-17 09:26AM  5 Biotech Stocks You'll Want to Watch in the 1st Quarter at Motley Fool
Jan-17-17 04:43PM  Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad
08:28AM  Key FDA Events to Watch Out for in Q1
Jan-15-17 07:10AM  Why Regeneron Pharmaceuticals, Inc. Stock Slipped 32.4% in 2016 at Motley Fool
Jan-13-17 04:32PM  Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink
Jan-12-17 12:04PM  Regeneron, Sanofi's Drug Manufacturing Plant Cleared at Investopedia
11:56AM  [$$] Sanofi confident it can overturn Praluent patent ruling at Financial Times
10:05AM  Merrill Lynch Has 4 Red-Hot Stocks to Buy With Up to 75% Upside Potential
Jan-11-17 01:26PM  Trump's Comments Are Big Pharma's Nightmare at Forbes
12:26PM  Trump's Comments Are Big Pharma's Nightmare
Jan-10-17 12:59PM  Todd Hagopian's Top Biotech Takeover Targets For 2017 at Forbes +5.05%
11:26AM  Regeneron CEO: The industry doesn't put patients first
09:30AM  The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals
08:53AM  2 Top Stocks in Biotech at Motley Fool
08:51AM  Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit
Jan-09-17 08:48PM  Regeneron CEO says Amgen not putting patients first in patent dispute Reuters
05:23PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
01:30PM  Morgan Stanley Cuts Regeneron Target On Praluent Patent Worries at
10:10AM  Company News for January 09, 2017
09:00AM  The FDA Approved Fewer Drugs in 2016: Here's Why
08:15AM  Blog Coverage Amgen's Legal Victory Blocks Rivals Sanofi and Regeneron from Selling their Cholesterol Drug in the US Accesswire
Jan-08-17 11:54PM  [$$] Regeneron Is Down, Not Out at The Wall Street Journal
02:02PM  Why Biotech Titans Are Clashing Over Cholesterol at Motley Fool
Jan-07-17 11:13AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer at Motley Fool
10:47AM  Judges unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake at MarketWatch
Jan-06-17 08:09PM  Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17) -5.84%
06:41PM  Why Regeneron Pharmaceuticals, Sears Holdings, and Shake Shack Slumped Today at Motley Fool
06:35PM  The Biggest Loser: Regeneron Sinks 5.8% at
04:56PM  [$$] Amgen Patent Win Boosts Odds of a Stock Comeback at
04:42PM  Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication
04:22PM  Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?
04:13PM  Regeneron, Sanofi Hammered After Judge Bans Amgen-Rivaling LDL-Buster
04:09PM  Disney's 'Tide Is Turning' But GoPro, McDonald's Served Downgrades
02:19PM  Facebook, Apple, Alphabet In Focus As Nasdaq, S&P 500 Hit New Highs
02:12PM  Regeneron: Let's Make a Deal? at
01:23PM  [$$] Regeneron Is Down, Not Out at The Wall Street Journal
12:57PM  Regeneron shares fall after judge blocks selling of cholesterol-lowering drug at CNBC
11:47AM  [$$] Regeneron shares tumble as US court blocks cholesterol drug at Financial Times
11:26AM  Here's Why Teva Shares Are Plummeting
11:09AM  Jim Cramer Sees Buying Opportunities in Praluent Patent Suit at TheStreet
10:55AM  Healthcare Stocks to Buy for 2017: Less Risky, More Risky, and Most Risky at Motley Fool
10:28AM  Could Amgen's Patent Victory Be Bad For Medicine? at Forbes
10:16AM  Regeneron, Sanofi Cholesterol Drug Gets Blocked at Investopedia
10:13AM  Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View
10:04AM  Gap soars on holiday sales cheer, Amgen jumps on patent win, Apple to open store in Samsung's home turf
09:40AM  Stock Open Lower After Jobs Report; Early Risers: Amgen, Ionis, Stemline
09:25AM  Use Regeneron's Current Weakness to Go Long
08:21AM  Morning Movers: JC Penney, Teva Pharmaceuticals Slump; Gap Soars at
08:18AM  Regeneron Cholesterol-Lowering Drug Banned From U.S. Market at TheStreet
08:13AM  Jobs growth disappoints, wages soar
07:45AM  Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent
07:24AM  Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View
06:13AM  U.S. stock futures tread water ahead of jobs report at MarketWatch
05:53AM  Sanofi Investors Have Worst Day in Six Months
05:53AM  5 Things You Must Know Before the Market Opens Friday
05:50AM  Regeneron Cholesterol-Lowering Drug Banned From U.S. Market in Stunning Loss to Amgen in Patent Case
12:08AM  [$$] Judge Rules Against Sanofi and Regeneron in Patent Case at The Wall Street Journal
Jan-05-17 08:37PM  [$$] Judge Rules Against Sanofi and Regeneron in Patent Case at The Wall Street Journal
08:00PM  Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection PR Newswire
06:09PM  Amgen shares soar as judge blocks sales of Regeneron drug at MarketWatch
05:52PM  Sanofi, Regeneron blocked from selling cholesterol drug
04:46PM  Amgen Wins Ban on Sanofis Praluent Cholesterol Drug Sales at Bloomberg
08:23AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : January 5, 2017
Jan-04-17 04:09PM  Regeneron, Sanofi LDL-Buster At Risk After Judge Upholds Amgen Patents
02:45PM  Regeneron continues New York investment spree at
02:30PM  Amgen Keeps Cholesterol Drug Patent Vs Regeneron at Investopedia
11:47AM  GM shares jump on sales climb; Tesla deliveries fall short; Oppenheimer says buy Panera Bread
11:06AM  Regeneron: Who Cares If Amgen Won the Latest Patent Battle? at
08:11AM  Early movers: GOOGL, AMZN, REGN, PFE, JNJ, HSY & more at CNBC
07:00AM  Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management PR Newswire
Jan-02-17 11:54AM  Biotech Stocks: What to Watch in 2017 at Motley Fool
Dec-30-16 04:04PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-29-16 05:29PM  4 Biotech Stocks with Bright Prospects in 2017
01:14PM  Vertex Pharmaceuticals Expects Strong Revenue Growth in 2016
07:12AM  Regeneron vs. Vertex: Which Stock is a Better Pick?
Dec-28-16 10:55AM  Why United Therapeutics Expects Strong Revenue Growth
09:30AM  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
06:52AM  Biotech plays for the new year
Dec-27-16 06:06PM  Bruce Pile's Top Recommendations For 2017 at Forbes
01:50PM  Regeneron Eyes A Comeback In 2017
08:53AM  Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead
Dec-26-16 07:36AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : December 26, 2016
Dec-22-16 02:01PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : December 22, 2016
02:00PM  Science Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health System PR Newswire
02:00PM  Regeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed PR Newswire
10:51AM  Bad News Bashes Biotech Investors... Again at Motley Fool
09:30AM  Regeneron Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
03:04AM  January could be particularly volatile for health care stocks, Goldman warns at MarketWatch
Dec-21-16 04:02PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles o
Dec-20-16 04:32PM  Regeneron Likely To Jump On Amgen LDL-Buster, But Expectations Too High
12:59PM  Reasons To Own Regeneron In 2017; CS Sees 30% Upside at
12:36PM  Celgene Added To CS Focus List; "The Best House In The Biotech Neighborhood" at
10:15AM  Regeneron Pharma upgraded by Credit Suisse
Dec-19-16 05:51PM  Fovista Flops: What's Next? at Motley Fool
09:30AM featured highlights: EnerSys, Monarch Casino & Resort, Grand Canyon Education, Ingredion and Regeneron Pharmaceuticals
09:28AM  7 Top Stocks We're Excited About Headed Into 2017 at Motley Fool
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products; and collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize fasinumab, an investigational NGF antibody in Phase III clinical development for osteoarthritis pain and in Phase II development for chronic low back pain. The company also has a strategic collaboration, option, and license agreement with Ocular Therapeutix for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other retinal diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM